Business Description
Revive Therapeutics Ltd
NAICS : 325412
SIC : 3741
ISIN : CA7615161030
Compare
Compare
Traded in other countries / regions
RVVTF.USARVV.Canada31R.Germany IPO Date
2017-04-21Description
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.54 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.4 | |||||
| 3-Year EPS without NRI Growth Rate | 28.2 | |||||
| 3-Year FCF Growth Rate | 9.1 | |||||
| 3-Year Book Growth Rate | -6.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.51 | |||||
| 9-Day RSI | 65.84 | |||||
| 14-Day RSI | 60.28 | |||||
| 6-1 Month Momentum % | -27.54 | |||||
| 12-1 Month Momentum % | -71.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.31 | |||||
| Quick Ratio | 0.31 | |||||
| Cash Ratio | 0.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.4 | |||||
| Shareholder Yield % | 1.42 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -11.63 | |||||
| ROA % | -8.49 | |||||
| ROIC % | -9.78 | |||||
| ROC (Joel Greenblatt) % | -91840 | |||||
| ROCE % | -11.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.93 | |||||
| EV-to-EBIT | -7.33 | |||||
| EV-to-EBITDA | -7.33 | |||||
| EV-to-FCF | -6.1 | |||||
| Earnings Yield (Greenblatt) % | -13.66 | |||||
| FCF Yield % | -15.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Revive Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.002 | ||
| Beta | -0.58 | ||
| Volatility % | 153.78 | ||
| 14-Day RSI | 60.28 | ||
| 14-Day ATR (€) | 0.001697 | ||
| 20-Day SMA (€) | 0.01303 | ||
| 12-1 Month Momentum % | -71.1 | ||
| 52-Week Range (€) | 0.0054 - 0.064 | ||
| Shares Outstanding (Mil) | 358.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Revive Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Revive Therapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Revive Therapeutics Ltd Frequently Asked Questions
What is Revive Therapeutics Ltd(FRA:31R)'s stock price today?
The current price of FRA:31R is €0.02. The 52 week high of FRA:31R is €0.06 and 52 week low is €0.01.
When is next earnings date of Revive Therapeutics Ltd(FRA:31R)?
The next earnings date of Revive Therapeutics Ltd(FRA:31R) is .
Does Revive Therapeutics Ltd(FRA:31R) pay dividends? If so, how much?
Revive Therapeutics Ltd(FRA:31R) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers